Clinical trial NCT06188533: Urinary Activin A as Apredictive Marker for Assessement of Acute Kidney Injury Severity in Patient Admitted at Assuit University Hospital
Official title: Urinary Activin A as Apredictive Marker for Assessement of Acute Kidney Injury Severity in Patient Admitted at Assuit University Hospital
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Urinary Activin A in AKI
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-01-03
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: * level of Activin A in urine correlate to the severity of the acute kidney injury (AKI), as the level of urinary Activin A in first stages of acute kidney injury is less than the second and third stages . (4)
* so follow up of urinary Activin A in patients with acute kidney injury can be avery useful biomarker for assessement of severity of acute kidney injury

Brief summary: Urinary Activin A as amarker for assessement of acute kidney injury severity in patient admitted at Assuit University Hospital

Detailed description: Acute kidney injury has been ahealth problem all over the world , It's prevelance in developing and developed countries is increasing due to pre renal , renal , post renal causes .

Estimates of AKI prevalence range from \<1% to 66%. These variations can be explained by not only population differences but also inconsistent use of standardized AKI classification criteria. The aetiology and incidence of AKI also differ between high-income and low-to-middle-income countries.(1)

* It can be presented in different stages according to AKIN classification (stage l (Increase in serum creatinine ≥0.3md/dl (≥26.4μmol/l) or increase to \>150% to 200% (1.5 fold to 2 fold) from baseline , and urine output (\<0.5 ml/kg/h for \>6 h ))

  * stage ll (Increase to \>200% to 300% (\>2 fold to 3 fold) from baseline) , and urine output (\<0.5 ml/kg/h for \>12 h ))
  * stage lll(Increase in serum creatinine to \>300% (\>3 fold) from baseline, or serum creatinine \>4.0mg/dl (\>354μmol/l) with acute increase of atleast 0.5mg/dl ) Urine output(\<0.3ml/kg/hr for 24 hours, or anuria for 12 hours). (2)
* In ischemic kidney, there is acytokine belong to the transforming growth factor (TGF)-B ( Activin A) that regulates the growth and differantiation of cell in variuos organs was significantly increasd in ischemic kidney . (3)
* level of Activin A in urine correlate to the severity of the acute kidney injury (AKI), as the level of urinary Activin A in first stages of acute kidney injury is less than the second and third stages . (4)
* so follow up of urinary Activin A in patients with acute kidney injury can be avery useful biomarker for assessement of severity of acute kidney injury. (4)

Eligibility criteria: Inclusion Criteria:

* The study will include patient with acute kidney injury with no history of chronic kidney diseases

Exclusion Criteria:

* patient with history of chronic kidney diseases , diseases associated with icreased activin A level such as ( heart failure , cancers , COPD , systemic sclerosis ,pregnant , viral infection , and Mycosis Fungoides and Sézary Syndrom

Primary outcomes:
measure: Urinary activin A in AKI
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: